NPR logo

Breast Cancer Gene Patents Challenged

  • Download
  • <iframe src="https://www.npr.org/player/embed/121343433/121343429" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Breast Cancer Gene Patents Challenged

Law

Breast Cancer Gene Patents Challenged

Breast Cancer Gene Patents Challenged

  • Download
  • <iframe src="https://www.npr.org/player/embed/121343433/121343429" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A landmark lawsuit is challenging the patents Myriad Genetics holds on the so-called breast cancer genes — patents that make Myriad the sole provider of a crucial genetic test. Do patents on genes spur research and innovation, or harm patients? Two experts share their views.

Guests:

Kevin Noonan, patent attorney, molecular biologist, partner, McDonnell, Boehnen, Hulbert & Berghoff, LLP, Chicago, Ill.

Daniel Ravicher, executive director, Public Patent Foundation, lecturer in law and associate director, Intellectual Property Law Program, Benjamin N. Cardozo School of Law, New York, N.Y.

Related NPR Stories